Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

Survival Rate Clinical Trial

Official title:

Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03052621
• Other study ID #: 635/59
• Status: Completed
• Phase: N/A
• First received: January 5, 2017
• Last updated: February 13, 2017
• Start date: January 1994
• Est. completion date: December 2016

Study information

• Verified date: February 2017
• Source: Queen Sirikit Centre for Breast Cancer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. While some centres showed the excellent healing of omental transposition. Meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. In the investigators' institute, omental transposition in breast cancer has been developed for twenty years. The only institute in Thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. This procedure is undertaken by single surgeon (Dr. K.J.). The investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 Gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. As a result, survival time could be improved.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The patients with omental transposition operation within King Chulalongkorn Memorial Hospital

• More than 18 years of age

Exclusion Criteria:

• The patients with refusal

Related Conditions & MeSH terms

• Survival Rate

Intervention

Procedure:
• Omental transposition
Harvesting the omentum to cover irradiated defects of breast cancer

Locations

Country	Name	City	State
Thailand	Queen Sirikit Centre for Breast Cancer	Bangkok

Sponsors (1)

Lead Sponsor	Collaborator
Queen Sirikit Centre for Breast Cancer

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival time		22 years